Andere Sprachen Intensity Therapeutics, Inc.

Aktien

A3C9BX

US45828J1034

INTS

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 31.05.2024			% 5 Tage	% 1. Jan.
4.97 ^USD	+0.61%		-1.58%	-42.01%

15.05.	Intensity Therapeutics, Inc. ernennt Thomas Dubin zum Mitglied des Board of Directors	CI
10.05.	Intensity Therapeutics, Inc. schließt einen Kooperationsvertrag mit der Schweizerischen Arbeitsgemeinschaft für Krebsforschung SAKK ab	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Intensity Therapeutics, Inc. Appoints Thomas Dubin to the Board of Directors	15.05.
Intensity Therapeutics, Inc. Enters into A Collaboration Agreement with the Swiss Group for Cancer Research SAKK	10.05.
Intensity Therapeutics Collaborates With Swiss Group on Clinical Research for Breast Cancer Trial	10.05.
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate	10.05.
Intensity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09.05.
Intensity Therapeutics, Inc. Announces Resignation of Daniel Donovan from Audit Committee of the Board of Directors	19.04.
Intensity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14.03.
Intensity Therapeutics Names Joseph Talamo as Finance Chief	12.12.
Sector Update: Health Care Stocks Rise Late Afternoon	08.12.
Sector Update: Health Care	08.12.
Top Midday Gainers	08.12.
Intensity Therapeutics Says Breast Cancer Treatment Showed Tumor Necrosis in Phase 2 Trial; Shares Jump	08.12.
Intensity Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13.11.
Intensity Therapeutics, Inc. Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023	02.11.
Intensity Therapeutics Gets Orphan Drug Label for Three Ingredients in INT230-6	07.09.23
Intensity Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14.08.23
INTENSITY THERAPEUTICS, INC. : Benchmark Company réitère son opinion positive sur le titre	18.07.23
Intensity Therapeutics Shares Surge in Nasdaq Debut After IPO Pricing	30.06.23
Intensity Therapeutics, Inc. has completed an IPO in the amount of $19.5 million.	29.06.23
Intensity Therapeutics, Inc. Announces Data from Its Ongoing Phase 1/2 Clinical Trial Demonstrating the Efficacy and Tolerability of Int230-6	03.06.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Intensity Therapeutics, Inc.

Aktien

A3C9BX

US45828J1034

INTS

Andere Sprachen

Filter